$ALT (+1,42 %) is now performing again after the last trial report and crash.
Of course, there is a lot of risk at this early stage.
Let's see how the FDA sees it later on.
Current developments against:
* Obesity and its associated diseases
* MASH (Metabolic Dysfunction-Associated Steatohepatitis)
* Alcohol use disorder (AUD)
* Alcohol-Associated Liver Disease (ALD)
